The impact of oral Polypodium leucotomos extract on ultraviolet B response: A human clinical study.
Level II
Where this comes from
- Record sourced from PubMed, PMID 28341348.
- Also identified by DOI 10.1016/j.jaad.2017.01.044 and PMC identifier 5730054.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is a rationale for adding systemic photoprotective agents to the current photoprotection regimen. This study was designed to objectively evaluate the molecular and photobiologic effects of oral administration of Polypodium leucotomos extract (PLE). In all, 22 subjects with Fitzpatrick skin phototype I to III were enrolled. On day 1, subjects were irradiated with visible light, ultraviolet (UV) A1, and UVB (using 308-nm excimer laser). Evaluation was done immediately and 24 hours after irradiation. On days 3 and 4, irradiation and evaluation process was repeated after ingestion of PLE. Clinical assessments and colorimetry data showed a decrease in UVB-induced changes in 17 of 22 subjects post-PLE administration; histology findings demonstrated such a decrease in all 22 subjects. Only 2 doses of PLE were given. Furthermore, subjects with skin phototypes I to III only were studied. The results suggest that PLE can potentially be used as an adjunctive agent to lessen the negative photobiologic effects of UVB.
Medical subject headings
- Plant Extracts
- Polypodium
- Skin
- Ultraviolet Rays